DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report sent to investors on Sunday. The firm issued a hold rating on the stock.

Separately, JMP Securities reiterated a “market outperform” rating and issued a $10.00 price target on shares of DBV Technologies in a report on Friday, January 10th.

DBV Technologies Price Performance

DBVT opened at $6.20 on Friday. DBV Technologies has a 12 month low of $2.20 and a 12 month high of $8.32. The stock has a market capitalization of $127.53 million, a P/E ratio of -1.38 and a beta of 0.71. The business has a 50 day simple moving average of $4.45 and a 200-day simple moving average of $3.85.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC purchased a new stake in DBV Technologies S.A. (NASDAQ:DBVT) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies as of its most recent SEC filing. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.